CANOQ vs. HSTO, WINT, ATNF, BJDX, NBSE, LSDI, PBLA, TIVC, GRI, and SQZ
Should you be buying Cano Health stock or one of its competitors? The main competitors of Cano Health include Histogen (HSTO), Windtree Therapeutics (WINT), 180 Life Sciences (ATNF), Bluejay Diagnostics (BJDX), NeuBase Therapeutics (NBSE), Lucy Scientific Discovery (LSDI), Panbela Therapeutics (PBLA), Tivic Health Systems (TIVC), GRI Bio (GRI), and SQZ Biotechnologies (SQZ). These companies are all part of the "medical" sector.
Cano Health (NYSE:CANOQ) and Histogen (NASDAQ:HSTO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk.
In the previous week, Histogen had 1 more articles in the media than Cano Health. MarketBeat recorded 1 mentions for Histogen and 0 mentions for Cano Health. Histogen's average media sentiment score of 0.30 beat Cano Health's score of 0.00 indicating that Histogen is being referred to more favorably in the news media.
Histogen has lower revenue, but higher earnings than Cano Health. Histogen is trading at a lower price-to-earnings ratio than Cano Health, indicating that it is currently the more affordable of the two stocks.
38.0% of Cano Health shares are held by institutional investors. 13.9% of Cano Health shares are held by insiders. Comparatively, 3.3% of Histogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Histogen received 7 more outperform votes than Cano Health when rated by MarketBeat users.
Cano Health has a beta of -0.28, meaning that its share price is 128% less volatile than the S&P 500. Comparatively, Histogen has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Cano Health has a net margin of -18.94% compared to Histogen's net margin of -65,142.11%. Cano Health's return on equity of -133.59% beat Histogen's return on equity.
Summary
Cano Health and Histogen tied by winning 7 of the 14 factors compared between the two stocks.
Get Cano Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for CANOQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CANOQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CANOQ vs. The Competition
Cano Health Competitors List
Related Companies and Tools
